ClinicalTrials.gg
Status unknownNCT05461924Updated Dec 1, 2022

The Long Term Outcomes After Pull-through of Long Segment Hirschsprung Disease

An observational study in Constipation, Incontinence and Hirschsprung Disease, Long-Segment, sponsored by Weibing Tang. Status unknown at 1 site in China. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Weibing Tang · Observational

How we know

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
50
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Constipation with a site in China — 35 open to participants now, 37 under way, 1 of them phase 3. Constipation · China.

Planned enrollment
13th of 16
50 · median 278
Started
2022
with 6 others
Observational
16 of 109
6 open now
Registered
55th of 109
by date

Among the 109 studies in Constipation with a site in China, this one is the 13th largest by planned enrollment of the 16 observational ones that give a count, is one of 7 that started in 2022, is one of 16 observational ones, and was the 55th registered.

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

35 of the 109 studies in Constipation with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Constipation with a site in China, or all of them as a file.
02

Study summary

Hirschsprung disease (HSCR) is characterized by the absence of ganglion cells (aganglionosis) in the distal bowel extending proximally for varying distances that results in persistent spasm in the affected bowel and functional intestinal obstruction. Patients can be classified as rectosigmoid HSCR when aganglionosis confined to the rectosigmoid and long-segment or total colonic HSCR when aganglionosis extends beyond the upper sigmoid. Aganglionosis of long-segment HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum. To date, there is insufficient evidence to recommend a preferred or superior method for the surgical repair for long-segment HSCR. In general, a pull-through with standard of care for the intestine and mesentery, which avoids excessive resection of the colon and coloanal reconstruction, is performed for long-segment HSCR.There are reports that a significant percentage of long-segment HSCR patients continue to have difficulty with soiling and incontinence,however there were also reports long-segment HSCR patients have the same continece as rectosigmoid HSCR.The outcome of long-segment HSCR should be thoroughly evaluated. The present study was designed to evaluate the long-term outcomes of long-segment HSCR.

Read the detailed description

Hirschsprung disease (HSCR) is characterized by the absence of ganglion cells (aganglionosis) in the distal bowel extending proximally for varying distances that results in persistent spasm in the affected bowel and functional intestinal obstruction. Patients can be classified as rectosigmoid HSCR when aganglionosis confined to the rectosigmoid and long-segment or total colonic HSCR when aganglionosis extends beyond the upper sigmoid. Aganglionosis of long-segment HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum. To date, there is insufficient evidence to recommend a preferred or superior method for the surgical repair for long-segment HSCR. In general, a pull-through with standard of care for the intestine and mesentery, which avoids excessive resection of the colon and coloanal reconstruction, is performed for long-segment HSCR.There are reports that a significant percentage of long-segment HSCR patients continue to have difficulty with soiling and incontinence,however there were also reports long-segment HSCR patients have the same continece as rectosigmoid HSCR.The outcome of long-segment HSCR should be thoroughly evaluated. The present study was designed to evaluate the long-term outcomes of long-segment HSCR.

The long-term outcome would be indicated by bowel function SCORE.

03

Conditions studied

  • Constipation
  • Incontinence
  • Hirschsprung Disease, Long-Segment
  • Long Term Adverse Effects

Keywords

  • Hirschsprung disease associated enterocolitis
  • bowel function
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with with rectosigmoid and long-segment Hirschsprung disease after operation.

The follow-up age must more than 3 years old.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinical diagnosis of Hirschsprung disease Must be performed with the operation of pull-through Must be followed up more than 3 years

Exclusion criteria

Exclusion Criteria:

Clinical diagnosis of Down syndrome Clinical diagnosis of tolal colonic Hirschsprung disease Clinical diagnosis of degestive malformation except Hirschsprung disease

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • long-segment HSCR

    Aganglionosis of non-rectosigmoid HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum

    Other: questionnaire survey

  • rectosigmoid HSCR

    Aganglionosis confined to the rectosigmoid

    Other: questionnaire survey

Interventions

  • Otherquestionnaire survey

    questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR

06

What researchers measure

Primary outcomes

  1. Bowel function score

    Bowel function was evaluated by the BFS (20 points), which was approved by Rintala in 1995 ; patients with a score \> 18 were considered to have normal bowel habits.

    Time frame: through study completion, an average of 5 year

Secondary outcomes

  1. Hirschspurng disease associated entrocolitis(HAEC)

    The guidelines for the diagnosis and management of HAEC were defined by the American Pediatric Surgical Association in 2017

    Time frame: through study completion, an average of 5 year

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210008, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Aug 2023, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2022
First posted
Jul 18, 2022
StartActual
Jul 15, 2022
Primary completionEst.
Aug 20, 2023
CompletionEst.
Aug 20, 2023
Last update
Dec 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05461924
Lead sponsor
Weibing Tang
Responsible party
Weibing Tang (Doctor, Nanjing Children's Hospital) — Sponsor-investigator
First posted
Jul 18, 2022
Start date
Jul 15, 2022
Primary completion
Aug 20, 2023 (estimated)
Completion
Aug 20, 2023 (estimated)
Last update
Dec 1, 2022

Study contacts

Weibing Tang, Dr
Contact
twbcn@163.com
8613851683700 ext. 025-83117354
Changgui Lu, Dr
Contact
luchanggui1984@163.com
8613770848448 ext. 025-83117354
Changgui Lu, Dr
principal investigator · Department of pediatric surgery of Children's hospital of Nanjing medical unverisity

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion